Ancobon
FDA Approves First Drug-Eluting Stent to Treat Peripheral Arterial Disease »
"The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked a"...
Read the FDA Approves First Drug-Eluting Stent to Treat Peripheral Arterial Disease article »
Ancobon
INDICATIONS
Ancobon (flucytosine) is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.
Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine.
Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported.
Ancobon (flucytosine) should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Ancobon (See Microbiology).
DOSAGE AND ADMINISTRATION
The usual dosage of Ancobon (flucytosine) is 50 to 150 mg/kg/day administered in divided doses at 6-hour intervals. Nausea or vomiting may be reduced or avoided if the capsules are given a few at a time over a 15-minute period. If the BUN or the serum creatinine is elevated, or if there are other signs of renal impairment, the initial dose should be at the lower level (see WARNINGS).
Ancobon (flucytosine) should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Ancobon (See Microbiology).
HOW SUPPLIED
Capsules, 250 mg (gray and green), imprinted ANCOBON® (flucytosine) 250 ICN, bottles of 100 (NDC 0187-3554-10). Capsules, 500 mg (gray and white), imprinted ANCOBON® (flucytosine) 500 ICN, bottles of 100 (NDC 0187-3555-10). Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F - 86°F).
Valeant Pharmaceuticals International, 3300 Hyland Avenue, Costa Mesa, California 92626. 714-545-0100. Rev. May 2006. FDA Rev date: 8/10/2006
Last reviewed on RxList: 10/8/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Ancobon Information
Ancobon - User Reviews
Ancobon User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Ancobon sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Heart Health
Get the latest treatment options.
Updated & New
